Ribbon Communications, Inc. RBBN 深 滬
等待開盤 11-05 09:30:00 美东时间
3.17
-0.190
-5.65%
華盛通- 最 高3.345
- 今 開3.32
- 成交量 65.77万股
- 最 低 3.16
- 昨 收 3.36
- 總市值 5.61亿
- 52周最高 5.38
- 市盈率 靜 --
- 換手率 0.37%
- 52周最低 3.01
- 委 比 -13.76%
- 總股本 1.77亿
- 歷史最高 11.25
- 量 比 0.75
- 振 幅 5.51%
- 歷史最低 1.78
- 每 手 1
- 風險率 0.33%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Insights into Adtran's Upcoming Earnings
Adtran (NASDAQ:ADTN) is gearing up to announce its quarterly earnings on Monday...
11-01 03:03
美股大行评级 | 上调目标价！特斯拉、赛默飞世尔、拉姆研究、波士顿科学、安诺电子、金沙集团等获众多机构评级
今日重点评级关注：摩根士丹利：维持Viking Therapeutics"超配"评级，目标价从98美元升至102美元；摩根大通：维持IDEAYA Biosciences"超配"评级，目标价从74美元升至79美元
10-24 09:51
Rosenblatt Maintains Buy on Ribbon Communications, Maintains $6 Price Target
Rosenblatt analyst Mike Genovese maintains Ribbon Communications (NASDAQ:RBBN) with a Buy and maintains $6 price target.
10-23 19:25
Ribbon Communications Lowers FY2025 Sales Guidance from $870.000M-$890.000M to $847.000M-$867.000M vs $876.867M Est
Ribbon Communications (NASDAQ:RBBN) lowers FY2025 sales outlook from $870.000 million-$890.000 million to $847.000 million-$867.000 million vs $876.867 million estimate.
10-23 04:38
Ribbon Communications shares are trading lower after the company reported worse-than-expected Q3 financial results and issued Q4 sales guidance below estimates.
Ribbon Communications shares are trading lower after the company reported worse...
10-23 04:37
Ribbon Comms Q3 Adj. EPS $0.04 Misses $0.06 Estimate, Sales $215.000M Miss $220.042M Estimate
Ribbon Comms (NASDAQ:RBBN) reported quarterly earnings of $0.04 per share which missed the analyst consensus estimate of $0.06 by 31.03 percent. This is a 20 percent decrease over earnings of $0.05 per share from the
10-23 04:04
Earnings Scheduled For October 22, 2025
Companies Reporting Before The Bell • Barclays (NYSE:BCS) is estimated to repor...
10-22 16:32
Earnings Outlook For Ribbon Comms
Ribbon Comms (NASDAQ:RBBN) will release its quarterly earnings report on Wednes...
10-22 05:01
Autolus Therapeutics to Present Clinical Data Update at the American College of Rheumatology (ACR) Convergence 2025
Autolus Therapeutics announced the online publication of an abstract for their ACR Convergence 2025 poster presentation, showcasing updated data from the CARLYSLE study on obe-cel for severe refractory systemic lupus erythematosus (srSLE). The Phase I study demonstrates a manageable safety profile with no dose-limiting toxicities or severe CRS/ICANS, alongside reductions in SLEDAI-2K scores and clinical benefit in all patients, including complete...
09-16 12:05
美股大行评级 | 潜在涨幅208.48%！HC Wainwright & Co.上调Microbot Medical目标价至12美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Microbot Medical"买入"评级，目标价从9美元升至12美元；Maxim Group：维持Neuphoria Therapeutics"买入"评级，目标价从18美元升至35美元
09-12 12:53
